Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 2011. The report details a specific share repurchase transaction executed on February 8, 2011, under authority granted by shareholders at the Annual General Meeting on May 6, 2010.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. The only financial metrics disclosed relate to the share buyback activity:
- Shares Purchased: 1,340,000 Ordinary shares of 25 pence each.
- Price Range: Highest price paid was 1,200.5 pence per share; lowest price paid was 1,188.5 pence per share.
- Treasury Holdings: 474,194,158 shares held in Treasury (8.36% of total issued share capital).
- Total Voting Rights Impact: Including unsettled purchases, Treasury holdings represent 9.19% of total voting rights.
- Shares in Issue: 5,196,553,692 shares (excluding Treasury shares).
Material Changes
The filing reports a reduction in outstanding shares due to the repurchase of 1,340,000 shares. Consequently, the percentage of total voting rights held in Treasury increased to 9.19% when including unsettled transactions. No other material changes to operations or financial position are disclosed in this document.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. The document is strictly a notification of a completed share repurchase and the resulting capital structure status.
Investor Verification Checklist
- Verify the total cost of the 1,340,000 shares purchased based on the disclosed price range.
- Confirm the impact of the 9.19% Treasury holding on the denominator for shareholder notification thresholds under Financial Services Authority rules.
- Check subsequent filings for the settlement status of the shares mentioned as "purchased but not yet settled."